Wound Biologics Market - A Global and Regional Analysis: Focus on Product, Region, Country-Level Analysis, and Competitive Landscape Analysis and Forecast, 2023-2030

Global Wound Biologics Market Industry Overview

The global wound biologics market was valued at $1,851.4 million in 2022 and is anticipated to grow to $3,321.5 million by the end of 2030. This market is expected to expand at a compound annual growth rate (CAGR) of 7.71% between 2023 and 2030. Such growth is being experienced by the wound biologics market, owing to increasing demand for treating wounds and burn injuries. Drivers of this growth include the rising incidence of burn injuries, the expanding prevalence of diabetic foot ulcers and pressure ulcers, and government-led initiatives aimed at enhancing wound care treatments.

Market Introduction

Wound biologics products are advanced medical materials derived from biological sources such as human cells, tissues, or natural substances. These products are specifically designed to facilitate wound healing and tissue regeneration in patients with various types of wounds, including chronic wounds such as diabetic ulcers, pressure ulcers, and venous ulcers, as well as acute wounds from injuries or surgeries. Wound biologics can include growth factors, extracellular matrices, cellular therapies, and bioengineered skin substitutes, all aimed at promoting the natural healing processes of the body to achieve better wound closure and tissue repair. One recent development that has taken place in the market was in March 2023 when BioTissue completed a facility expansion and renovation in Doral, Florida, to support the growing demand and future expansion of its biologics product portfolio.

Market Segmentation:

Segmentation 1: by Product

• Growth Factors
• Skin Substitutes
• Topical Agents

Skin Substitutes to Lead the Global Wound Biologics Market (by Product)

Based on product, the wound biologics market is led by skin substitutes, which held a 63.78% share in 2022.

Segmentation 2: by Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Russian Federation
  • Turkey
  • Poland
  • Belgium
  • Sweden
  • Ireland
  • Norway
  • Austria
  • Denmark
  • Finland
  • Portugal
  • Czech Republic
  • Romania
  • Greece
  • Slovakia
  • Ukraine
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Malaysia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Colombia
  • Argentina
  • Chile
• Rest-of-the-World

Regionally, North America maintains a dominant position, and it is expected to grow through a steady compound annual growth rate (CAGR) of 6.66% from 2023 to 2030. This sustained growth can be attributed to the region's advanced healthcare infrastructure, widespread awareness of wound management, and a notable increase in chronic wounds among its aging populace.

The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics products, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions. The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions.

Asia-Pacific and the Rest-of-the-World regions are projected to experience the highest growth rates, with CAGRs of 11.49% and 11.29%, respectively, indicating a rapidly expanding market presence. The growth in these regions is likely driven by improving healthcare infrastructure, rising awareness of effective wound care, and increasing accessibility to advanced medical treatments. Overall, the wound biologics market globally has been characterized by regional growth patterns influenced by healthcare advancements, demographic shifts, and a collective focus on improving wound care outcomes.

Recent Developments in the Wound Biologics Market

• In May 2023, Cellularity disclosed a significant purchase order amounting to $45 million in accordance with the first private label agreement in the Middle East for Cellularity Inc.'s halal-certified biomaterial products. The products, namely Biovance, Biovance 3L, Interfyl, and CentaFlex have obtained halal certification.
• In January 2022, Gunze Limited announced the commencement of Epiflex sales by Gunze Medical Limited, marking the first and only approved product available in Japan. It is important to note that Epiflex is a registered trademark of MiMedx Group, Inc.

How can this Report add value to an Organization?

Product/Innovation Strategy: The report can highlight current market gaps and emerging patient needs, guiding companies in developing new products or enhancing existing offerings.

Growth/Marketing Strategy: Regional analysis offers insights into market size, growth rates, and competitive landscapes across different territories, assisting in strategic planning for geographic expansion or consolidation.

Competitive Strategy: Understanding future market trends and growth forecasts allows companies to anticipate changes in the competitive landscape, adjust their strategies accordingly, and identify early opportunities for innovation and expansion.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. A historical year analysis has been done for the period FY2019-FY2021. The market size has been estimated for FY2022 and projected for the period FY2023-FY2030
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of upstream and downstream products of wound biologics.
• The market contribution of wound biologics products anticipated to be launched in the future has been calculated based on the historical analysis of the solutions.
• Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
• The market has been mapped based on the available wound biologics solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in wound biologics, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and salespersons have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Percentage split of individual markets for regional analysis

Secondary Research:

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global competitive landscape of the wound biologics market is defined by the presence of several key players, each contributing to the market's growth through innovation, business expansion, funding, strategic partnerships, and a focus on expanding product portfolios. Leading companies in this space are distinguished by their commitment to research and development, which enables them to introduce advanced wound care solutions that address a range of needs, from basic wound protection to complex wound management scenarios.

Some prominent names established in this market are:

• AlloSource
• LifeNet Health
• Smith & Nephew plc.
• Sanara MedTech Inc.
• Mtf Biologics
• Becton, Dickinson and Company
• MiMedx Group, Inc.
• TissueTech, Inc.